• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • English
    • Français
  • Canada
    • Répertoire du site Sandoz
Sandoz : A Novartis Division
  • Our Work
    • What We Do
    • Quality Generics
    • Biopharmaceuticals
    • Specialty Products
  • About Us
    • Who We Are
    • Corporate Responsibility
    • Doing Business Responsibly
    • Contact Us
    • Grants, Donations and Sponsorships
  • Products
    • Consumers
    • Patients
    • Healthcare Professionals
    • Patient Support Programs
  • News
    • Media Releases
    • Media Resource Center
    • Stay Up-To-Date
  • Careers
    • Available Positions
    • Diversity & Inclusion
    • Our Benefits
  • Sandoz-Connect Portal
Search
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
  • Jump to Comments
Stories/Global Impact

Biosimilars reimbursement update

As of September 30, 2020, PrZiextenzo® (pegfilgrastim) and PrRiximyo®(rituximab for injection) are now eligible for reimbursement in Quebec through the RAMQ’s Public Prescription Drug Insurance Plan.

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals.

As of October 7, 2020, PrRiximyo® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.

For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.

Oct 19, 2020

Biosimilars reimbursement update

As of September 30, 2020, PrZiextenzo® (pegfilgrastim) and PrRiximyo®(rituximab for injection) are now eligible for reimbursement in Quebec through the RAMQ’s Public Prescription Drug Insurance Plan.

In addition, both biosimilars are on the list of medicines and establishments for use in Canadian hospitals. 

As of October 7, 2020, PrRiximyo® is also eligible for reimbursement in Nova Scotia through the Nova Scotia Pharmacare.

For more information on Sandoz biosimilars click here and to get evidence-based information on biosimilars in Canada visit The Biosimilars Generation web site.

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Global Impact

Novartis expands humanitarian efforts in Ukraine through donation of essential medicines

Global Impact

Sandoz Canada Completes Sale of Sterile Injectable Medicine Manufacturing Plant

Global Impact

Sandoz Canada launches PrSandoz® Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent to PrTecfidera*

You are here

  1. Home ›
  2. Global Impact ›

Sandoz Canada

  • Notre travail
  • Our Work
  • À propos de nous
  • About Us
  • Produits
  • Products
  • Nouvelles
  • News
  • Carrières
  • Careers
  • Contactez-nous
  • Contact Us
  • Nous trouver
  • Office Locations
  • Rester à jour
  • Stay up to date

Subscribe to Sandoz

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • RSS
  • Sandoz Site Directory
© 2023 Sandoz AG

This site is intended for an audience in Canada

  • Termes d'utilisation
  • Terms of Use
  • Politique sur la vie privée
  • Privacy Policy
  • Terms of Trade
  • Return Policy
  • Politique d'achat
  • Politique de retour
  • Cookie Settings